Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJohannes Schneider-Thoma, Nobuyuki Nomura, Natalia E Fares-Otero, Susan Illing, Bram W C Storosum, Jasper B Zantvoord, Georgios Schoretsanitis, Christian Schwarz, Julia Schulz, Horst Naiser, Karl Heinz Möhrmann, John M Davis
Abstract
Authors
No local citing links have been materialized yet.
Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases
10.1016/s0140-6736(25)02365-7 · 2026
Secondary effects of antipsychotics: women at greater risk than men
10.1093/schbul/sbn023 · 2009
Women and psychosis: a guide to evidence-based, hormone-informed care
10.1016/s2215-0366(26)00016-7 · 2026
The impact of sex and age on antipsychotic serum concentrations
10.1093/schbul/sbaf217 · 2026
Gender differences in the prescribing of antipsychotic drugs
10.1176/appi.ajp.161.8.1324 · 2004
Do women need a change in dose of prescription drugs with onset of menopause? Time to find out
10.1186/s12916-025-04253-1 · 2025
Sex and gender equity in research: rationale for the SAGER guidelines and recommended use
10.1186/s41073-016-0007-6 · 2016
Gender differences in the response to antipsychotic medication in patients with schizophrenia: an individual patient data meta-analysis of placebo-controlled studies
10.1016/j.psychres.2022.114997 · 2023
Women's sexual dysfunction associated with psychiatric disorders and their treatment
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1177/1745506518762664 · 2018
Evidence-based recommendations for the pharmacological treatment of women with schizophrenia spectrum disorders
10.1007/s11920-023-01460-6 · 2023
Clinical practice guideline on the choice of first antipsychotic medicine for females experiencing a first-episode of psychosis
10.1093/schbul/sbag023 · 2026
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
10.1016/s2215-0366(22)00304-2 · 2022
Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: a systematic review
10.1016/j.jad.2024.02.038 · 2024
Get real in individual participant data (IPD) meta-analysis: a review of the methodology
10.1002/jrsm.1160 · 2015
Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials
10.4088/jcp.13m08853 · 2014
Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses
10.1503/cmaj.200077 · 2020
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
10.1016/j.jclinepi.2003.08.009 · 2004
Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
10.1136/bmj.j573 · 2017
Sex differences in the efficacy and tolerability of antipsychotic drugs in people with an acute exacerbation of schizophrenia: protocol for an individual-participant-data, dose-response, network meta-analysis
10.12688/f1000research.169873.1 · 2025
Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement
10.1001/jama.2015.3656 · 2015
GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research
2017
Standardized effect sizes are far from “Standardized”: a primer and empirical illustration in depression psychotherapy meta-analyses
10.1371/journal.pmen.0000347 · 2025
Equipercentile linking of the BPRS and the PANSS
10.1016/j.euroneuro.2012.11.004 · 2013
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia
10.1016/j.schres.2012.01.031 · 2012
Reclassifying dropouts from antipsychotic trials due to study-reported adverse events: a systematic review and individual-participant-data meta-analyses
10.1016/j.euroneuro.2026.112874 · 2026
Pitfalls of using the risk ratio in meta-analysis
10.1002/jrsm.1347 · 2019
Unresolved referenced work
1987
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)
10.1177/02698811231205688 · 2023
Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis
10.1016/j.eclinm.2026.103847 · 2026
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019
ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis
10.1136/bmj-2023-076754 · 2023
Unresolved referenced work
Kept as external metadata until matched
Fitting linear mixed-effects models using lme4
10.18637/jss.v067.i01 · 2015
How to perform a meta-analysis with R: a practical tutorial
10.1136/ebmental-2019-300117 · 2019
netmeta: an R package for network meta-analysis using frequentist methods
10.18637/jss.v106.i02 · 2023
Multivariate dose-response meta-analysis: the dosresmeta R package
10.18637/jss.v072.c01 · 2016
Hyperprolactinaemia in first episode psychosis—a longitudinal assessment
10.1016/j.schres.2017.07.037 · 2017
Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality
10.1055/s-0043-107243 · 2017
The effects of antipsychotics on prolactin levels and women's menstruation
10.1155/2013/502697 · 2013
Antipsychotics and hyperprolactinaemia: clinical recommendations
10.1177/0269881107087346 · 2008
Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials
10.1016/s2215-0366(26)00174-4 · doi-reference
Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse
10.1093/schbul/sbac139 · doi-reference
Trajectories of clozapine concentrations in women across menopausal age
10.1093/schbul/sbaf186 · doi-reference
Evaluation of reported claims of sex-based differences in treatment effects across meta-analyses: a meta-research study
10.1136/bmjebm-2024-113359 · doi-reference
Treatment effect modification due to comorbidity: individual participant data meta-analyses of 120 randomised controlled trials
10.1371/journal.pmed.1004176 · doi-reference
Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials
10.1001/jamainternmed.2016.9125 · doi-reference
Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis
10.1136/bmj-2024-082974 · doi-reference
Breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia
10.1007/s40618-024-02492-2 · doi-reference
Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
10.1016/s2215-0366(21)00241-8 · doi-reference
Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition
10.1007/s00737-024-01491-9 · doi-reference